Who
Andrew R. Robbins
President and CEO
Company insider
Files Form 4 as: President and CEO, Cogent Biosciences; Director, Harpoon Therapeutics; COO, Array Biopharma.
In numbers
- Trades disclosed
- 86
- Buys
- 0
- Sells
- 4
- Bought
- $0
- Sold
- $8.3M
- Companies
- 3
- Companies where not an officer
- 1
- First trade
- 1 Apr 2014
- Last trade
- 19 May 2026
- Last filed
- 21 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 19 May 2026filed 21 May 2026 | COGT Cogent BiosciencesBiotechnology | SEC FORM 4 Code G | —160,000 at $0.00 | filing |
| 19 May 2026filed 21 May 2026 | COGT Cogent BiosciencesBiotechnology | SEC FORM 4 Code G | —160,000 at $0.00 | filing |
| 19 May 2026filed 21 May 2026 | COGT Cogent BiosciencesBiotechnology | SEC FORM 4 Code G | —160,000 at $0.00 | filing |
| 19 May 2026filed 21 May 2026 | COGT Cogent BiosciencesBiotechnology | SEC FORM 4 Code G | —160,000 at $0.00 | filing |
| 17 Dec 2025filed 19 Dec 2025 | COGT Cogent Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —245,000 at $0.00 | filing |
| 17 Dec 2025filed 19 Dec 2025 | COGT Cogent BiosciencesBiotechnology | SEC FORM 4 Code A | —185,000 at $0.00 | filing |
| 17 Dec 2025filed 19 Dec 2025 | COGT Cogent BiosciencesBiotechnology | SEC FORM 4 Code A | —840,000 at $0.00 | filing |
| 17 Dec 2025filed 19 Dec 2025 | COGT Cogent BiosciencesBiotechnology | SEC FORM 4 Code F | $14.5M367,497 at $39.45 | filing |
| 23 Jan 2025filed 27 Jan 2025 | COGT Cogent Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —915,000 at $0.00 | filing |
| 11 Mar 2024filed 11 Mar 2024 | Harpoon Therapeuticsoption or derivative | SEC FORM 4 Code D | —1,016 | filing |
| 11 Mar 2024filed 11 Mar 2024 | Harpoon Therapeuticsoption or derivative | SEC FORM 4 Code D | —2,300 | filing |
| 11 Mar 2024filed 11 Mar 2024 | Harpoon Therapeutics | SEC FORM 4 Code D | —5,000 | filing |
| 23 Jan 2024filed 25 Jan 2024 | COGT Cogent Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,100,000 at $0.00 | filing |
| 27 Nov 2023filed 28 Nov 2023 | Harpoon Therapeutics | SEC FORM 4 Code A | —5,000 at $0.00 | filing |
| 22 Jun 2023filed 23 Jun 2023 | Harpoon Therapeuticsoption or derivative | SEC FORM 4 Code A | —23,000 at $0.00 | filing |
| 13 Feb 2023filed 15 Feb 2023 | COGT Cogent Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —525,000 at $0.00 | filing |
| 22 Jun 2022filed 24 Jun 2022 | Harpoon Therapeuticsoption or derivative | SEC FORM 4 Code A | —10,167 at $0.00 | filing |
| 25 Jan 2022filed 27 Jan 2022 | COGT Cogent Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | $3.4M690,000 at $4.94 | filing |
| 4 May 2021filed 14 May 2021 | Harpoon Therapeuticsoption or derivative | SEC FORM 4 Code A | —10,167 at $0.00 | filing |
| 4 May 2021filed 7 May 2021 | Harpoon Therapeuticsoption or derivative | SEC FORM 4 Code A | —10,167 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.